Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Arrive AI and DXC Technology partner to bring delivery tech to factories